Furthermore, Vivimed obtained ANDA approval for Metronidazole and same is commercialised. During November 2016, the Company acquired ANDA of Zolpidem and the file transfer has successfully been completed. lt is expected to be commercialised by Q4 FY2O17. Vivimed is on track of its filing targets and has successfully completed 3 ANDA filings during FY2017 and expect one more filing to be completed by Q4 FY2017. These products provide vertical integration with the inhouse APls.